1245575-24-9

Basic information

• Product Name: 3-(phenylsulfonyl)-4-(4-(2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoyloxy)but-2-ynyloxy)-1,2,5-oxadiazole-2-oxide
• CAS NO: 1245575-24-9
• Molecular Weight: 650.817
• Mol File: 1245575-24-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(phenylsulfonyl)-4-(4-(2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoyloxy)but-2-ynyloxy)-1,2,5-oxadiazole-2-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(phenylsulfonyl)-4-(4-(2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoyloxy)but-2-ynyloxy)-1,2,5-oxadiazole-2-oxide(1245575-24-9)
• EPA Substance Registry System: 3-(phenylsulfonyl)-4-(4-(2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoyloxy)but-2-ynyloxy)-1,2,5-oxadiazole-2-oxide(1245575-24-9)

Safety Data

• Hazardous Substances Data: 1245575-24-9(Hazardous Substances Data)

Upstream product

• 66074-00-8 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 

Relevant articles and documents

Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: Synthesis and evaluation of antihepatocellular carcinoma activity

Figure Presented. Novel furoxan-based nitric oxide (NO) releasing derivatives (8a-p) of farnesylthiosalicylic acid (FTS) were synthesized. Compound 8l displayed the strongest inhibition on the proliferation of human hepatocellular carcinoma (HCC) cells in vitro, superior to FTS, sorafenib, and furoxan moiety, selectively induced high frequency of HCC cell apoptosis, and produced high levels of NO in HCC cells but not in nontumor liver cells. Furthermore, 8l exhibited low acute toxicity to mice and significantly inhibited the growth of HCC tumors in vivo and the Ras-related signaling in the tumors. Therefore, our novel findings may provide a new framework for the design of new NO-releasing furoxan/FTS hybrids for the intervention of human HCC.